CelaCare Technologies, Inc.
Specialty pharmaceutical company engaged in development of novel antimicrobial topical and oral formulations
CelaCare Technologies, Inc. is an early-stage Harding University spin-out specialty pharmaceutical company. The company is engaged in the development of novel formulations of antimicrobials for mucosal and topical therapy for both human and veterinary markets. The company’s initial products are based on a combination of a proprietary ISO qualified silver citrate complex, an antimicrobial salt with demonstrated potency, and acemannan, a known immunomodulator manufactured in accordance with US FDA current Good Manufacturing Practices. This combination possesses unique synergistic antimicrobial effects allowing for significantly reduced silver concentrations while providing potent activity against fungal pathogens and multi-drug resistant bacterial strains. In addition, formulations possess functional properties for improved tissue repair and pain relief. The company has filed patent applications on this unique combination thus providing foundational protection for a planned portfolio of products.